Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
The Lancet. Oncology|April 26, 2025
TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trialAziz Zaanan, Olivier Bouché, Christelle de la Fouchardière, et al.
Liver Cancer|December 15, 2025
Cabozantinib for Hepatocellular Carcinoma in Real-World Practice (CLERANCE): A Prospective, Interventional StudyFrançois Villeret, Mohamed Bouattour, Jean-Frédéric Blanc, et al.
Clinics and Research in Hepatology and Gastroenterology|December 14, 2024
Induction triplet chemotherapy in patients with rectal adenocarcinoma and synchronous metastases, an AGEO-FFCD studyVictoire Dabout, Laurent Mineur, David Tougeron, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 9, 2024
Relative dose intensity of first-line triplet chemotherapy in metastatic colorectal cancerJulien Hoba, Adrien Grancher, Vincent Hautefeuille, et al.
Swiss Medical Weekly|December 29, 2021
Local treatment in the setting of de novo metastatic rectal cancer: reappraisal of prognostic factorsNicolas Vial, Julien Langrand-Escure, Peng Diao, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 3, 2021
Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trialClaire Gallois, Jean-François Emile, Stefano Kim, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 26, 2021
Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiologyPeter R Galle, Masatoshi Kudo, Josep M Llovet, et al.
European Journal of Cancer (Oxford, England : 1990)|July 5, 2022
Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancerValentin Derangère, Julie Lecuelle, Come Lepage, et al.
American Journal of Medical Genetics. Part A|September 20, 2015
Compound heterozygous PKHD1 variants cause a wide spectrum of ductal plate malformationsJean-Benoît Courcet, Anne Minello, Fabienne Prieur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2026
Circulating tumor DNA dynamics and clinical outcomes in patients with advanced Colorectal Cancer treated with cetuximab-based induction and maintenance treatmentValérie Boige, Olivier Bouché, Claire Mulot, et al.
Pageof 10